Why Mankind Pharma is different from other Pharma Companies?

#MankindPharma #StockAnalysis #FundamentalAnalysis #PharmaceuticalStocks #Investing #FinancialAnalysis #StockMarket #InvestmentResearch #ValueInvesting #StockValuation #MarketAnalysis #InvestmentEducation #InvestmentTips #StocksToWatch

Explore a comprehensive fundamental analysis of Mankind Pharma in this detailed video. We delve into the financial performance, key metrics, and strategic outlook of Mankind Pharma, one of India's leading pharmaceutical companies. Discover insights into revenue trends, profitability ratios, and growth prospects that influence the company's stock valuation.

00:00 Start
01:27 About Mankind Pharma
01:53 Mankind Pharma History
02:55 Mankind Pharma- Key Business
03:50 Domestic Formulation Business
05:22 Increasing Share of Chronic Segment
06:30 Consumer Healthcare
08:34 Distribution Strength
08:46 Key Brands- Therapeutic Areas
09:03 Intellectual Property Rights
10:00 International Business
11:56 Industry Overview
13:07 IPM
13:30 Growth Rate: Therapy
14:16 Consumer Healthcare Market
15:03 Review of a Consolidation Trend in IPM & FDC Announcements
16:44 National List of Essential Medicine (NLEM) Impact
17:44 Prescriber-Related Trends in IPM
18:06 Financial Statements – Financial Insights (Quarterly)
18:59 Therapy Wise Sales Mix (%)
19:11 Financial Statements – Financial Insights (Yearly)
22:22 Financial Statements – Financial Insights
23:05 Competitive Landscape
25:20 Governance
25:37 Shareholding Pattern
25:54 Risks
26:26 Valuations- Share Price Performance

Complete Fundamental Stock Analysis Tool - Stock-o-meter:
https://investyadnya.in/stock-o-meter

Research Based Ready-made Model Portfolios:
https://investyadnya.in/model-portfolios

Comprehensive Mutual Fund Reviews:
https://investyadnya.in/fund-o-meter

Yadnya Books and eBooks now available:
On Amazon - https://amzn.to/2XKtlks
On our website - https://investyadnya.in/books

Find us on Social Media and stay connected:
Whatsapp Channel - https://whatsapp.com/channel/0029Va6N...
Blog - https://blog.investyadnya.in
Telegram - http://t.me/InvestYadnya
Facebook Page -   / investyadnya  
Twitter -   / investyadnya  

#InvestYadnya #YIA

LEGAL DISCLAIMER:

Use of this information is at the user's own risk. The Company and its directors, associates and employees will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided herein. The investment discussed or views expressed herein may not be suitable for all investors. The users should rely on their own research and analysis and should consult their investment advisors to determine the merit, risks and suitability of recommendation. Past performance is not a guarantee for future performance or future results. Information herein is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The images used may be copyright of the company or third party. As a condition to using the services, the user agrees to the terms of use of the website and the services.


DISCLOSURES UNDER SEBI (RESEARCH ANALYST) REGULATIONS, 2014:

Yadnya Academy Pvt. Ltd. (InvestYadnya) is registered with SEBI under SEBI (Research Analyst) Regulations, 2014 with registration no. INH000008349.
Disclosure with regard to ownership and material conflicts of interest
1. Neither Research Analyst nor the entity nor his associates or relatives have any financial interest in the subject Company;
2. Neither Research Analyst nor the entity nor its associates or relatives have actual / beneficial ownership of one per cent or more securities of the subject Company, at the end of the month immediately preceding the date of publication of the research report or date of public appearance;
3. Neither Research Analyst nor the entity nor its associates or his relatives have any other material conflict of interest at the time of publication of the research report or at the time of public appearance.
Disclosure with regard to receipt of Compensation
1. The Research Entity and its associates have not received compensation from the subject company in the past twelve months.
2. The subject company is not or was not a client during the twelve months preceding the date of recommendation.